A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Stopped This study has been withdrawn due to an internal decision. The decision was not due to any safety concerns with study drug.

Conditions

• Guillain-Barré Syndrome

Interventions

• DRUG: Crovalimab
• DRUG: Placebo
• DRUG: Intravenous immunoglobulin therapy

Sponsor

Hoffmann-La Roche

Collaborators

• [object Object]